TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia (Q33429430)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia (English)

1 reference

Europe PubMed Central

26 July 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

Waldenström macroglobulinemia

1 reference

based on heuristic

inferred from title

Paul G. Richardson

5

object named as

Paul G Richardson

1 reference

Europe PubMed Central

26 July 2017

1

object named as

Irene M Ghobrial

1 reference

Europe PubMed Central

26 July 2017

author name string

David S Siegel

2

1 reference

Europe PubMed Central

26 July 2017

Ravi Vij

3

1 reference

Europe PubMed Central

26 July 2017

Jesus G Berdeja

4

1 reference

Europe PubMed Central

26 July 2017

Rachel Neuwirth

6

1 reference

Europe PubMed Central

26 July 2017

Chirag G Patel

7

1 reference

Europe PubMed Central

26 July 2017

Fabian Zohren

8

1 reference

Europe PubMed Central

26 July 2017

Jeffrey L Wolf

9

1 reference

Europe PubMed Central

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 January 2016

1 reference

Europe PubMed Central

26 July 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

American Journal of Hematology

1 reference

Europe PubMed Central

26 July 2017

91

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

400-405

1 reference

Europe PubMed Central

26 July 2017

mTOR: from growth signal integration to cancer, diabetes and ageing

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

mTOR signaling in disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

mTOR and cancer: insights into a complex relationship

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Rapamycin passes the torch: a new generation of mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Target of rapamycin signaling in leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Utility of mTOR inhibition in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

The translational landscape of mTOR signalling steers cancer initiation and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Defining the role of TORC1/2 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

SEOM clinical guidelines for the treatment of renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Dissecting the role of mTOR: lessons from mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Development of PI3K inhibitors: lessons learned from early clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Metabolic complications with the use of mTOR inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24300

21 January 2018

Identifiers

10.1002/AJH.24300

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33429430&oldid=1902171492"